Dr. Reddy`s Laboratories announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company (Takeda) to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Dr. Reddy`s will market Vonoprazan tablets under its own trademark VONO� to be available in two strengths, 10mg and 20mg. Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), are very common in India. A pan-Indian cross-sectional survey of clinicians showed APD prevalence to be in the range of 37-39%. It is more common in the 18-59 age group, with heart burn and epigastric pain as common symptoms. Powered by Capital Market - Live News

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 27 July 2024.Powered by Capital Market - Live News

Dr Reddys Laboratories has received reaffirmation in credit rating at ICRA AA+; Stable for bank facilities aggregating Rs 1,200 crore. Powered by Capital Market - Live News

Net profit of Dr Reddy`s Laboratories rose 36.42% to Rs 1309.80 crore in the quarter ended March 2024 as against Rs 960.10 crore during the previous quarter ended March 2023. Sales rose 12.49% to Rs 7083.00 crore in the quarter ended March 2024 as against Rs 6296.80 crore during the previous quarter ended March 2023.For the full year,net profit rose 23.75% to Rs 5577.90 crore in the year ended March 2024 as against Rs 4507.30 crore during the previous year ended March 2023. Sales rose 13.54% to Rs 27916.40 crore in the year ended March 2024 as against Rs 24587.90 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales7083.006296.80 12 27916.4024587.90 14 OPM %25.8524.36 -28.4225.82 - PBDT1972.901644.60 20 8671.007298.70 19 PBT1605.201329.10 21 7201.006048.50 19 NP1309.80960.10 36 5577.904507.30 24 Powered by Capital Market - Live News

Dr Reddys Laboratories announced that the 40th Annual General Meeting(AGM) of the company will be held on 29 July 2024.Powered by Capital Market - Live News